Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation. A Perfect Combination for Cancer Therapy.

Advances in Cancer Research

Volumn 130, Issue , 2016, Pages 55-111

  Zahnow, C A ^a   Topper, M ^a   Stone, M ^a   Murray Stewart, T ^a   Li, H ^a   Baylin, S B ^a   Casero, R A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

DNA methyltransferase inhibitors; Drug synergy; Epigenetic therapy; Histone deacetylation and methylation inhibitors; Solid tumors

Indexed keywords

AZACITIDINE; BIOLOGICAL MARKER; DNA METHYLTRANSFERASE INHIBITOR; ENTINOSTAT; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; MONOAMINE OXIDASE INHIBITOR; NUCLEAR RECEPTOR COREPRESSOR; PANOBINOSTAT; POLYAMINE DERIVATIVE; ROMIDEPSIN; VORINOSTAT; ZINC; ANTINEOPLASTIC AGENT; HISTONE; HISTONE DEACETYLASE; RNA;

ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; CANCER THERAPY; COMPLEX FORMATION; DEACETYLATION; DNA METHYLATION; EPIGENETICS; GENE ACTIVATION; GENE SILENCING; HISTONE DEMETHYLATION; HUMAN; IMMUNE RESPONSE; NONHUMAN; RNA METABOLISM; SIGNAL TRANSDUCTION; DRUG POTENTIATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; NEOPLASM; PROMOTER REGION;

ANTINEOPLASTIC AGENTS; DNA METHYLATION; DRUG SYNERGISM; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; NEOPLASMS; PROMOTER REGIONS, GENETIC; RNA; TRANSCRIPTION, GENETIC;

EID: 84961230886     PISSN: 0065230X     EISSN: 21625557     Source Type: Book Series    
DOI: 10.1016/bs.acr.2016.01.007     Document Type: Chapter

References (259)

1. Aagaard L., Laible G., Selenko P., Schmid M., Dorn R., Schotta G., et al. Functional mammalian homologues of the Drosophila PEV-modifier Su(var)3-9 encode centromere-associated proteins which complex with the heterochromatin component M31. The EMBO Journal 1999, 18(7):1923-1938.
2. Abele R., Clavel M., Dodion P., Bruntsch U., Gundersen S., Smyth J., et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. European Journal of Cancer and Clinical Oncology 1987, 23(12):1921-1924.
3. Ahuja N., Easwaran H., Baylin S.B. Harnessing the potential of epigenetic therapy to target solid tumors. The Journal of Clinical Investigation 2014, 124(1):56-63.
4. Aimiuwu J., Wang H., Chen P., Xie Z., Wang J., Liu S., et al. RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia. Blood 2012, 119(22):5229-5238.
5. Aldana-Masangkay G.I., Sakamoto K.M. The role of HDAC6 in cancer. Journal of Biomedicine & Biotechnology 2011, 2011:875824.
6. Allis C., Jenuwein T., Reinberg D., Caparros M. Epigenetics 2015, Vol. 2. Cold Spring Harbor Laboratories Press, New York. 2nd ed.
7. Amato R.J. Inhibition of DNA methylation by antisense oligonucleotide MG98 as cancer therapy. Clinical Genitourinary Cancer 2007, 5(7):422-426.
8. Antequera F., Macleod D., Bird A.P. Specific protection of methylated CpGs in mammalian nuclei. Cell 1989, 58(3):509-517.
9. Appleton K., Mackay H.J., Judson I., Plumb J.A., McCormick C., Strathdee G., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Journal of Clinical Oncology 2007, 25(29):4603-4609.
10. Arce C., Perez-Plasencia C., Gonzalez-Fierro A., de la Cruz-Hernandez E., Revilla-Vazquez A., Chavez-Blanco A., et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One 2006, 1:e98.
11. Arrowsmith C.H., Bountra C., Fish P.V., Lee K., Schapira M. Epigenetic protein families: A new frontier for drug discovery. Nature Reviews. Drug Discovery 2012, 11(5):384-400.
12. Asgatay S., Champion C., Marloie G., Drujon T., Senamaud-Beaufort C., Ceccaldi A., et al. Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1. Journal of Medicinal Chemistry 2014, 57(2):421-434.
13. Avvakumov G.V., Walker J.R., Xue S., Li Y., Duan S., Bronner C., et al. Structural basis for recognition of hemi-methylated DNA by the SRA domain of human UHRF1. Nature 2008, 455(7214):822-825.
14. Bachman K.E., Rountree M.R., Baylin S.B. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. The Journal of Biological Chemistry 2001, 276(34):32282-32287.
15. Bantscheff M., Hopf C., Savitski M.M., Dittmann A., Grandi P., Michon A.M., et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nature Biotechnology 2011, 29(3):255-265.
16. Barth T., Imhof A. Fast signals and slow marks: The dynamics of histone modifications. Trends in Biochemical Sciences 2010, 35(11):618-626.
17. Basavapathruni A., Jin L., Daigle S.R., Majer C.R., Therkelsen C.A., Wigle T.J., et al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chemical Biology & Drug Design 2012, 80(6):971-980.
18. Bauman J., Verschraegen C., Belinsky S., Muller C., Rutledge T., Fekrazad M., et al. A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies. Cancer Chemotherapy and Pharmacology 2012, 69(2):547-554.
19. Baylin S.B. Tying it all together: Epigenetics, genetics, cell cycle, and cancer. Science 1997, 277(5334):1948-1949.
20. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: A fundamental aspect of neoplasia. Advances in Cancer Research 1998, 72:141-196.
21. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome-Biological and translational implications. Nature Reviews. Cancer 2011, 11(10):726-734.
22. Baylin S.B., Makos M., Wu J.J., Yen R.W., de Bustros A., Vertino P., et al. Abnormal patterns of DNA methylation in human neoplasia: Potential consequences for tumor progression. Cancer Cells 1991, 3(10):383-390.
23. Belinsky S.A., Klinge D.M., Stidley C.A., Issa J.P., Herman J.G., March T.H., et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Research 2003, 63(21):7089-7093.
24. Bergy M.E., Herr R.R. Microbiological production of 5-azacytidine. II. Isolation and chemical structure. Antimicrobial Agents and Chemotherapy 1966, 6:625-630.
25. Beumer J.H., Eiseman J.L., Parise R.A., Joseph E., Holleran J.L., Covey J.M., et al. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Clinical Cancer Research 2006, 12(24):7483-7491.
26. Bhalla S., Balasubramanian S., David K., Sirisawad M., Buggy J., Mauro L., et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clinical Cancer Research 2009, 15(10):3354-3365.
27. Bianchi M., Polticelli F., Ascenzi P., Botta M., Federico R., Mariottini P., et al. Inhibition of polyamine and spermine oxidases by polyamine analogues. The FEBS Journal 2006, 273(6):1115-1123.
28. Billam M., Sobolewski M.D., Davidson N.E. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Research and Treatment 2010, 120(3):581-592.
29. Boivin A.J., Momparler L.F., Hurtubise A., Momparler R.L. Antineoplastic action of 5-aza-2'-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anti-Cancer Drugs 2002, 13(8):869-874.
30. Boyer L.A., Langer M.R., Crowley K.A., Tan S., Denu J.M., Peterson C.L. Essential role for the SANT domain in the functioning of multiple chromatin remodeling enzymes. Molecular Cell 2002, 10(4):935-942.
31. Bradner J.E., West N., Grachan M.L., Greenberg E.F., Haggarty S.J., Warnow T., et al. Chemical phylogenetics of histone deacetylases. Nature Chemical Biology 2010, 6(3):238-243.
32. Braiteh F., Soriano A.O., Garcia-Manero G., Hong D., Johnson M.M., Silva Lde P., et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clinical Cancer Research 2008, 14(19):6296-6301.
33. Cai Y., Geutjes E.J., de Lint K., Roepman P., Bruurs L., Yu L.R., et al. The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 2014, 33(17):2157-2168.
34. Cameron E.E., Bachman K.E., Myohanen S., Herman J.G., Baylin S.B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genetics 1999, 21(1):103-107.
35. Candelaria M., Gallardo-Rincon D., Arce C., Cetina L., Aguilar-Ponce J.L., Arrieta O., et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors. Annals of Oncology 2007, 18(9):1529-1538.
36. Chai G., Li L., Zhou W., Wu L., Zhao Y., Wang D., et al. HDAC inhibitors act with 5-aza-2'-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS ONE 2008, 3(6):e2445.
37. Champion C., Guianvarc'h D., Senamaud-Beaufort C., Jurkowska R.Z., Jeltsch A., Ponger L., et al. Mechanistic insights on the inhibition of c5 DNA methyltransferases by zebularine. PLoS ONE 2010, 5(8):e12388.
38. Chen M.Y., Liao W.S., Lu Z., Bornmann W.G., Hennessey V., Washington M.N., et al. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer 2011, 117(19):4424-4438.
39. Chen L., MacMillan A.M., Chang W., Ezaz-Nikpay K., Lane W.S., Verdine G.L. Direct identification of the active-site nucleophile in a DNA (cytosine-5)-methyltransferase. Biochemistry 1991, 30(46):11018-11025.
40. Chen R.Z., Pettersson U., Beard C., Jackson-Grusby L., Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998, 395(6697):89-93.
41. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-Miswritten, misinterpreted and mis-erased in human cancers. Nature Reviews. Cancer 2010, 10(7):457-469.
42. Chiappinelli K.B., Strissel P.L., Desrichard A., Li H., Henke C., Akman B., et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 2015, 162(5):974-986.
43. Chu B.F., Karpenko M.J., Liu Z., Aimiuwu J., Villalona-Calero M.A., Chan K.K., et al. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 2013, 71(1):115-121.
44. Chuang J.C., Yoo C.B., Kwan J.M., Li T.W., Liang G., Yang A.S., et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Molecular Cancer Therapeutics 2005, 4(10):1515-1520.
45. Chuikov S., Kurash J.K., Wilson J.R., Xiao B., Justin N., Ivanov G.S., et al. Regulation of p53 activity through lysine methylation. Nature 2004, 432(7015):353-360.
46. Cihak A. Biological effects of 5-azacytidine in eukaryotes. Oncology 1974, 30(5):405-422.
47. Clavel M., Monfardini S., Fossa S., Smyth J., Renard J., Kaye S.B. 5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group. Annals of Oncology 1992, 3(5):399-400.
48. Codina A., Love J.D., Li Y., Lazar M.A., Neuhaus D., Schwabe J.W. Structural insights into the interaction and activation of histone deacetylase 3 by nuclear receptor corepressors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(17):6009-6014.
49. Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A., et al. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clinical Cancer Research 2006, 12(4):1168-1174.
50. Coronel J., Cetina L., Pacheco I., Trejo-Becerril C., Gonzalez-Fierro A., de la Cruz-Hernandez E., et al. A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results. Medical Oncology 2011, 28(Suppl. 1):S540-S546.
51. Cowger J.J., Zhao Q., Isovic M., Torchia J. Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: Identification of a ZNF217 consensus recognition sequence. Oncogene 2007, 26(23):3378-3386.
52. Deaton A.M., Bird A. CpG islands and the regulation of transcription. Genes and Development 2011, 25(10):1010-1022.
53. Defossez P.A. Ceci n'est pas une DNMT: Recently discovered functions of DNMT2 and their relation to methyltransferase activity (comment on DOI 10.1002/bies.201300088). Bioessays 2013, 35(12):1024.
54. Denis H., Ndlovu M.N., Fuks F. Regulation of mammalian DNA methyltransferases: A route to new mechanisms. EMBO Reports 2011, 12(7):647-656.
55. Denslow S.A., Wade P.A. The human Mi-2/NuRD complex and gene regulation. Oncogene 2007, 26(37):5433-5438.
56. Dimitrova E., Turberfield A.H., Klose R.J. Histone demethylases in chromatin biology and beyond. EMBO Reports 2015, 16(12):1620-1639.
57. Ebert D.H., Gabel H.W., Robinson N.D., Kastan N.R., Hu L.S., Cohen S., et al. Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR. Nature 2013, 499(7458):341-345.
58. Ecke I., Petry F., Rosenberger A., Tauber S., Monkemeyer S., Hess I., et al. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Research 2009, 69(3):887-895.
59. Eden S., Hashimshony T., Keshet I., Cedar H., Thorne A.W. DNA methylation models histone acetylation. Nature 1998, 394(6696):842.
60. Egger G., Liang G., Aparicio A., Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429(6990):457-463.
61. Ellis L., Atadja P.W., Johnstone R.W. Epigenetics in cancer: Targeting chromatin modifications. Molecular Cancer Therapeutics 2009, 8(6):1409-1420.
62. Evangelista M., Tian H., de Sauvage F.J. The hedgehog signaling pathway in cancer. Clinical Cancer Research 2006, 12(20 Pt. 1):5924-5928.
63. Falkenberg K.J., Johnstone R.W. Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nature Reviews. Drug Discovery 2014, 13(9):673-691.
64. Fang F., Balch C., Schilder J., Breen T., Zhang S., Shen C., et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010, 116(17):4043-4053.
65. Fang M.Z., Wang Y., Ai N., Hou Z., Sun Y., Lu H., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research 2003, 63(22):7563-7570.
66. Federico R., Leone L., Botta M., Binda C., Angelini R., Venturini G., et al. Inhibition of pig liver and Zea mays L. polyamine oxidase: A comparative study. Journal of Enzyme Inhibition 2001, 16(2):147-155.
67. Fitzpatrick P.F. Oxidation of amines by flavoproteins. Archives of Biochemistry and Biophysics 2010, 493(1):13-25.
68. Forneris F., Binda C., Adamo A., Battaglioli E., Mattevi A. Structural basis of LSD1-CoREST selectivity in histone H3 recognition. The Journal of Biological Chemistry 2007, 282(28):20070-20074.
69. Forneris F., Binda C., Vanoni M.A., Mattevi A., Battaglioli E. Histone demethylation catalysed by LSD1 is a flavin-dependent oxidative process. FEBS Letters 2005, 579(10):2203-2207.
70. Foster C.T., Dovey O.M., Lezina L., Luo J.L., Gant T.W., Barlev N., et al. Lysine-specific demethylase 1 regulates the embryonic transcriptome and CoREST stability. Molecular and Cellular Biology 2010, 30(20):4851-4863.
71. Fotheringham S., Epping M.T., Stimson L., Khan O., Wood V., Pezzella F., et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis. Cancer Cell 2009, 15(1):57-66.
72. Fu S., Hu W., Iyer R., Kavanagh J.J., Coleman R.L., Levenback C.F., et al. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer 2011, 117(8):1661-1669.
73. Fujita N., Watanabe S., Ichimura T., Tsuruzoe S., Shinkai Y., Tachibana M., et al. Methyl-CpG binding domain 1 (MBD1) interacts with the Suv39h1-HP1 heterochromatic complex for DNA methylation-based transcriptional repression. The Journal of Biological Chemistry 2003, 278(26):24132-24138.
74. Fuks F., Burgers W.A., Brehm A., Hughes-Davies L., Kouzarides T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nature Genetics 2000, 24(1):88-91.
75. Fuks F., Hurd P.J., Deplus R., Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Research 2003, 31(9):2305-2312.
76. Ghoshal K., Datta J., Majumder S., Bai S., Kutay H., Motiwala T., et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Molecular and Cellular Biology 2005, 25(11):4727-4741.
77. Glozak M.A., Seto E. Histone deacetylases and cancer. Oncogene 2007, 26(37):5420-5432.
78. Goll M.G., Bestor T.H. Eukaryotic cytosine methyltransferases. Annual Review of Biochemistry 2005, 74:481-514.
79. Goll M.G., Kirpekar F., Maggert K.A., Yoder J.A., Hsieh C.L., Zhang X., et al. Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 2006, 311(5759):395-398.
80. Graca I., Sousa E.J., Baptista T., Almeida M., Ramalho-Carvalho J., Palmeira C., et al. Anti-tumoral effect of the non-nucleoside DNMT inhibitor RG108 in human prostate cancer cells. Current Pharmaceutical Design 2014, 20(11):1803-1811.
81. Guenther M.G., Barak O., Lazar M.A. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Molecular and Cellular Biology 2001, 21(18):6091-6101.
82. Gui C.Y., Ngo L., Xu W.S., Richon V.M., Marks P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(5):1241-1246.
83. Guil S., Esteller M. DNA methylomes, histone codes and miRNAs: Tying it all together. The International Journal of Biochemistry & Cell Biology 2009, 41(1):87-95.
84. Hakimi M.A., Bochar D.A., Chenoweth J., Lane W.S., Mandel G., Shiekhattar R. A core-BRAF35 complex containing histone deacetylase mediates repression of neuronal-specific genes. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(11):7420-7425.
85. Hanka L.J., Evans J.S., Mason D.J., Dietz A. Microbiological production of 5-azacytidine. I. Production and biological activity. Antimicrobial Agents and Chemotherapy (Bethesda) 1966, 6:619-624.
86. Hansen K.D., Timp W., Bravo H.C., Sabunciyan S., Langmead B., McDonald O.G., et al. Increased methylation variation in epigenetic domains across cancer types. Nature Genetics 2011, 43(8):768-775.
87. Harris W.J., Huang X., Lynch J.T., Spencer G.J., Hitchin J.R., Li Y., et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012, 21(4):473-487.
88. Hayami S., Kelly J.D., Cho H.S., Yoshimatsu M., Unoki M., Tsunoda T., et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. International Journal of Cancer 2011, 128(3):574-586.
89. Herman J.G., Baylin S.B. Gene silencing in cancer in association with promoter hypermethylation. The New England Journal of Medicine 2003, 349(21):2042-2054.
90. Hermann A., Schmitt S., Jeltsch A. The human Dnmt2 has residual DNA-(cytosine-C5) methyltransferase activity. The Journal of Biological Chemistry 2003, 278(34):31717-31721.
91. Hojfeldt J.W., Agger K., Helin K. Histone lysine demethylases as targets for anticancer therapy. Nature Reviews. Drug Discovery 2013, 12(12):917-930.
92. Hollenbach P.W., Nguyen A.N., Brady H., Williams M., Ning Y., Richard N., et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010, 5(2):e9001.
93. Huang Y., Greene E., Murray Stewart T., Goodwin A.C., Baylin S.B., Woster P.M., et al. Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes. Proceedings of the National Academy of Sciences of the United States of America 2007, 104(19):8023-8028.
94. Huang Y., Marton L.J., Woster P.M., Casero R.A. Polyamine analogues targeting epigenetic gene regulation. Essays in Biochemistry 2009, 46:95-110.
95. Huang J., Sengupta R., Espejo A.B., Lee M.G., Dorsey J.A., Richter M., et al. p53 is regulated by the lysine demethylase LSD1. Nature 2007, 449(7158):105-108.
96. Huang Y., Stewart T.M., Wu Y., Baylin S.B., Marton L.J., Perkins B., et al. Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clinical Cancer Research 2009, 15(23):7217-7228.
97. Huang Y., Vasilatos S.N., Boric L., Shaw P.G., Davidson N.E. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Research and Treatment 2012, 131(3):777-789.
98. Humphrey G.W., Wang Y., Russanova V.R., Hirai T., Qin J., Nakatani Y., et al. Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. The Journal of Biological Chemistry 2001, 276(9):6817-6824.
99. Issa J.P., Baylin S.B., Herman J.G. DNA methylation changes in hematologic malignancies: Biologic and clinical implications. Leukemia 1997, 11(Suppl. 1):S7-S11.
100. Issa J.P., Roboz G., Rizzieri D., Jabbour E., Stock W., O'Connell C., et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study. The Lancet. Oncology 2015, 16(9):1099-1110.
101. Jackson J.P., Lindroth A.M., Cao X., Jacobsen S.E. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 2002, 416(6880):556-560.
102. Jair K.W., Bachman K.E., Suzuki H., Ting A.H., Rhee I., Yen R.W., et al. De novo CpG island methylation in human cancer cells. Cancer Research 2006, 66(2):682-692.
103. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293(5532):1074-1080.
104. Jia D., Jurkowska R.Z., Zhang X., Jeltsch A., Cheng X. Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation. Nature 2007, 449(7159):248-251.
105. Jin L., Hanigan C.L., Wu Y., Wang W., Park B.H., Woster P.M., et al. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1(DNA methyltransferase 1)-independent manner. The Biochemical Journal 2013, 449(2):459-468.
106. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nature Reviews. Genetics 2002, 3(6):415-428.
107. Jones P.A., Baylin S.B. The epigenomics of cancer. Cell 2007, 128(4):683-692.
108. Jones S.F., Infante J.R., Spigel D.R., Peacock N.W., Thompson D.S., Greco F.A., et al. Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors. Cancer Investigation 2012, 30(6):481-486.
109. Jones P.A., Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20(1):85-93.
110. Juergens R.A., Wrangle J., Vendetti F.P., Murphy S.C., Zhao M., Coleman B., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discovery 2011, 1(7):598-607.
111. Juo Y.Y., Gong X.J., Mishra A., Cui X., Baylin S.B., Azad N.S., et al. Epigenetic therapy for solid tumors: From bench science to clinical trials. Epigenomics 2015, 7(2):215-235.
112. Jurkowska R.Z., Jurkowski T.P., Jeltsch A. Structure and function of mammalian DNA methyltransferases. Chembiochem 2011, 12(2):206-222.
113. Jurkowski T.P., Meusburger M., Phalke S., Helm M., Nellen W., Reuter G., et al. Human DNMT2 methylates tRNA(Asp) molecules using a DNA methyltransferase-like catalytic mechanism. RNA 2008, 14(8):1663-1670.
114. Juttermann R., Li E., Jaenisch R. Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(25):11797-11801.
115. Kahl P., Gullotti L., Heukamp L.C., Wolf S., Friedrichs N., Vorreuther R., et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Research 2006, 66(23):11341-11347.
116. Karytinos A., Forneris F., Profumo A., Ciossani G., Battaglioli E., Binda C., et al. A novel mammalian flavin-dependent histone demethylase. The Journal of Biological Chemistry 2009, 284(26):17775-17782.
117. Kauffman E.C., Robinson B.D., Downes M.J., Powell L.G., Lee M.M., Scherr D.S., et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Molecular Carcinogenesis 2011, 50(12):931-944.
118. Khan O., Fotheringham S., Wood V., Stimson L., Zhang C., Pezzella F., et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(14):6532-6537.
119. Khoddami V., Cairns B.R. Identification of direct targets and modified bases of RNA cytosine methyltransferases. Nature Biotechnology 2013, 31(5):458-464.
120. Kim K.H., Kim W., Howard T.P., Vazquez F., Tsherniak A., Wu J.N., et al. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2. Nature Medicine 2015, 21(12):1491-1496.
121. Kim C.H., Marquez V.E., Mao D.T., Haines D.R., McCormack J.J. Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. Journal of Medicinal Chemistry 1986, 29(8):1374-1380.
122. Kim K., Skora A.D., Li Z., Liu Q., Tam A.J., Blosser R.L., et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proceedings of the National Academy of Sciences of the United States of America 2014, 111(32):11774-11779.
123. Kim M., Thompson L.A., Wenger S.D., O'Bryant C.L. Romidepsin: A histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma. The Annals of Pharmacotherapy 2012, 46(10):1340-1348.
124. King M.Y., Redman K.L. RNA methyltransferases utilize two cysteine residues in the formation of 5-methylcytosine. Biochemistry 2002, 41(37):11218-11225.
125. Klose R.J., Kallin E.M., Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nature Reviews. Genetics 2006, 7(9):715-727.
126. Kuo H.K., Griffith J.D., Kreuzer K.N. 5-Azacytidine induced methyltransferase-DNA adducts block DNA replication in vivo. Cancer Research 2007, 67(17):8248-8254.
127. Lacoste N., Utley R.T., Hunter J.M., Poirier G.G., Cote J. Disruptor of telomeric silencing-1 is a chromatin-specific histone H3 methyltransferase. The Journal of Biological Chemistry 2002, 277(34):30421-30424.
128. Leclercq S., Gueugnon F., Boutin B., Guillot F., Blanquart C., Rogel A., et al. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma. The European Respiratory Journal 2011, 38(5):1105-1116.
129. Lee H.Z., Kwitkowski V.E., Del Valle P.L., Ricci M.S., Saber H., Habtemariam B.A., et al. FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clinical Cancer Research 2015, 21(12):2666-2670.
130. Lee Y.S., Lim K.H., Guo X., Kawaguchi Y., Gao Y., Barrientos T., et al. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Research 2008, 68(18):7561-7569.
131. Lee M.G., Wynder C., Cooch N., Shiekhattar R. An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 2005, 437(7057):432-435.
132. Lee M.G., Wynder C., Schmidt D.M., McCafferty D.G., Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chemistry & Biology 2006, 13(6):563-567.
133. Li E., Bestor T.H., Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69(6):915-926.
134. Li B., Carey M., Workman J.L. The role of chromatin during transcription. Cell 2007, 128(4):707-719.
135. Li H., Chiappinelli K.B., Guzzetta A.A., Easwaran H., Yen R.W., Vatapalli R., et al. Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget 2014, 5(3):587-598.
136. Li L.H., Olin E.J., Buskirk H.H., Reineke L.M. Cytotoxicity and mode of action of 5-azacytidine on L1210 leukemia. Cancer Research 1970, 30(11):2760-2769.
137. Lillico R., Sobral M.G., Stesco N., Lakowski T.M. HDAC inhibitors induce global changes in histone lysine and arginine methylation and alter expression of lysine demethylases. Journal of Proteomics 2016, 133:125-133.
138. Lim S., Janzer A., Becker A., Zimmer A., Schule R., Buettner R., et al. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis 2010, 31(3):512-520.
139. Lin J., Gilbert J., Rudek M.A., Zwiebel J.A., Gore S., Jiemjit A., et al. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clinical Cancer Research 2009, 15(19):6241-6249.
140. Ling Y., Sankpal U.T., Robertson A.K., McNally J.G., Karpova T., Robertson K.D. Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1 modulates its interaction with histone deacetylases (HDACs) and its capacity to repress transcription. Nucleic Acids Research 2004, 32(2):598-610.
141. Lombardi P.M., Cole K.E., Dowling D.P., Christianson D.W. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Current Opinion in Structural Biology 2011, 21(6):735-743.
142. Lu L.W., Chiang G.H., Medina D., Randerath K. Drug effects on nucleic acid modification. I. A specific effect of 5-azacytidine on mammalian transfer RNA methylation in vivo. Biochemical and Biophysical Research Communications 1976, 68(4):1094-1101.
143. Lu L.J., Randerath K. Effects of 5-azacytidine on transfer RNA methyltransferases. Cancer Research 1979, 39(3):940-949.
144. Lu Y., Wajapeyee N., Turker M.S., Glazer P.M. Silencing of the DNA mismatch repair gene MLH1 induced by hypoxic stress in a pathway dependent on the histone demethylase LSD1. Cell Reports 2014, 8(2):501-513.
145. Luszczek W., Cheriyath V., Mekhail T.M., Borden E.C. Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: Correlation of resistance with IFN-stimulated gene expression. Molecular Cancer Therapeutics 2010, 9(8):2309-2321.
146. Lyko F., Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. Journal of the National Cancer Institute 2005, 97(20):1498-1506.
147. Maes T., Mascaro C., Ortega A., Lunardi S., Ciceri F., Somervaille T.C., et al. KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease. Epigenomics 2015, 7(4):609-626.
148. Mann B.S., Johnson J.R., Cohen M.H., Justice R., Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. The Oncologist 2007, 12(10):1247-1252.
149. Mann B.S., Johnson J.R., He K., Sridhara R., Abraham S., Booth B.P., et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clinical Cancer Research 2007, 13(8):2318-2322.
150. Margueron R., Reinberg D. The polycomb complex PRC2 and its mark in life. Nature 2011, 469(7330):343-349.
151. Matei D., Fang F., Shen C., Schilder J., Arnold A., Zeng Y., et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Research 2012, 72(9):2197-2205.
152. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Research 2006, 66(7):3541-3549.
153. McGrath J., Trojer P. Targeting histone lysine methylation in cancer. Pharmacology & Therapeutics 2015, 150:1-22.
154. McLean C.M., Karemaker I.D., van Leeuwen F. The emerging roles of DOT1L in leukemia and normal development. Leukemia 2014, 28(11):2131-2138.
155. Metzger E., Wissmann M., Yin N., Muller J.M., Schneider R., Peters A.H., et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005, 437(7057):436-439.
156. Mohammad H.P., Smitheman K.N., Kamat C.D., Soong D., Federowicz K.E., Van Aller G.S., et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 2015, 28(1):57-69.
157. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., Ayoub J. Pilot phase I-II study on 5-aza-2'-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997, 8(4):358-368.
158. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics 2010, 42(2):181-185.
159. Motorin Y., Lyko F., Helm M. 5-Methylcytosine in RNA: Detection, enzymatic formation and biological functions. Nucleic Acids Research 2010, 38(5):1415-1430.
160. Mould D.P., McGonagle A.E., Wiseman D.H., Williams E.L., Jordan A.M. Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: Clinical significance and progress to date. Medicinal Research Reviews 2015, 35(3):586-618.
161. Murray-Stewart T., Woster P.M., Casero R.A. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines. Amino Acids 2014, 46(3):585-594.
162. Nan X., Ng H.H., Johnson C.A., Laherty C.D., Turner B.M., Eisenman R.N., et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393(6683):386-389.
163. Nervi C., De Marinis E., Codacci-Pisanelli G. Epigenetic treatment of solid tumours: A review of clinical trials. Clinical Epigenetics 2015, 7:127.
164. New M., Olzscha H., La Thangue N.B. HDAC inhibitor-based therapies: Can we interpret the code?. Molecular Oncology 2012, 6(6):637-656.
165. Newman E.M., Morgan R.J., Kummar S., Beumer J.H., Blanchard M.S., Ruel C., et al. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemotherapy and Pharmacology 2015, 75(3):537-546.
166. Nowotarski S.L., Pachaiyappan B., Holshouser S.L., Kutz C.J., Li Y., Huang Y., et al. Structure-activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures. Bioorganic & Medicinal Chemistry 2015, 23(7):1601-1612.
167. O'Hagan H.M., Mohammad H.P., Baylin S.B. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genetics 2008, 4(8):e1000155.
168. O'Hagan H.M., Wang W., Sen S., Destefano Shields C., Lee S.S., Zhang Y.W., et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 2011, 20(5):606-619.
169. Ohm J.E., McGarvey K.M., Yu X., Cheng L., Schuebel K.E., Cope L., et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nature Genetics 2007, 39(2):237-242.
170. Ooi S.K., Qiu C., Bernstein E., Li K., Jia D., Yang Z., et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 2007, 448(7154):714-717.
171. Parry L., Clarke A.R. The roles of the methyl-CpG binding proteins in cancer. Genes & Cancer 2011, 2(6):618-630.
172. Pasini A., Delmonte A., Tesei A., Calistri D., Giordano E. Targeting chromatin-mediated transcriptional control of gene expression in non-small cell lung cancer therapy: Preclinical rationale and clinical results. Drugs 2015, 75(15):1757-1771.
173. Peng D., Kryczek I., Nagarsheth N., Zhao L., Wei S., Wang W., et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 2015, 527(7577):249-253.
174. Perissi V., Jepsen K., Glass C.K., Rosenfeld M.G. Deconstructing repression: Evolving models of co-repressor action. Nature Reviews. Genetics 2010, 11(2):109-123.
175. Pohlmann P., DiLeone L.P., Cancella A.I., Caldas A.P., Dal Lago L., Campos O., et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. American Journal of Clinical Oncology 2002, 25(5):496-501.
176. Portela A., Esteller M. Epigenetic modifications and human disease. Nature Biotechnology 2010, 28(10):1057-1068.
177. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clinical Cancer Research 2009, 15(12):3958-3969.
178. Prusevich P., Kalin J.H., Ming S.A., Basso M., Givens J., Li X., et al. A selective phenelzine analogue inhibitor of histone demethylase LSD1. ACS Chemical Biology 2014, 9(6):1284-1293.
179. Rai K., Chidester S., Zavala C.V., Manos E.J., James S.R., Karpf A.R., et al. Dnmt2 functions in the cytoplasm to promote liver, brain, and retina development in zebrafish. Genes & Development 2007, 21(3):261-266.
180. Rao Z.Y., Cai M.Y., Yang G.F., He L.R., Mai S.J., Hua W.F., et al. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis 2010, 31(9):1576-1583.
181. Rao R., Nalluri S., Kolhe R., Yang Y., Fiskus W., Chen J., et al. Treatment with panobinostat induces glucose-regulated protein 78 acetylation and endoplasmic reticulum stress in breast cancer cells. Molecular Cancer Therapeutics 2010, 9(4):942-952.
182. Rea S., Eisenhaber F., O'Carroll D., Strahl B.D., Sun Z.W., Schmid M., et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000, 406(6796):593-599.
183. Ren J., Singh B.N., Huang Q., Li Z., Gao Y., Mishra P., et al. DNA hypermethylation as a chemotherapy target. Cellular Signalling 2011, 23(7):1082-1093.
184. Richardson P.G., Harvey R.D., Laubach J.P., Moreau P., Lonial S., San-Miguel J.F. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: Pharmacology and clinical outcomes. Expert Review of Clinical Pharmacology 2016, 9(1):35-48.
185. Robertson K.D., Ait-Si-Ali S., Yokochi T., Wade P.A., Jones P.L., Wolffe A.P. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nature Genetics 2000, 25(3):338-342.
186. Rodriguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nature Medicine 2011, 17(3):330-339.
187. Ropero S., Esteller M. The role of histone deacetylases (HDACs) in human cancer. Molecular Oncology 2007, 1(1):19-25.
188. Rose N.R., Klose R.J. Understanding the relationship between DNA methylation and histone lysine methylation. Biochimica et Biophysica Acta 2014, 1839(12):1362-1372.
189. Roulois D., Loo Yau H., Singhania R., Wang Y., Danesh A., Shen S.Y., et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 2015, 162(5):961-973.
190. Rountree M.R., Bachman K.E., Baylin S.B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nature Genetics 2000, 25(3):269-277.
191. Sampath D., Rao V.A., Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003, 22(56):9063-9074.
192. San-Miguel J.F., Richardson P.G., Gunther A., Sezer O., Siegel D., Blade J., et al. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. Journal of Clinical Oncology 2013, 31(29):3696-3703.
193. Santi D.V., Norment A., Garrett C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proceedings of the National Academy of Sciences of the United States of America 1984, 81(22):6993-6997.
194. Sato T., Kaneda A., Tsuji S., Isagawa T., Yamamoto S., Fujita T., et al. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Scientific Reports 2013, 3:1911.
195. Schaefer M., Hagemann S., Hanna K., Lyko F. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer Research 2009, 69(20):8127-8132.
196. Schaefer M., Lyko F. Solving the Dnmt2 enigma. Chromosoma 2010, 119(1):35-40.
197. Schenk T., Chen W.C., Gollner S., Howell L., Jin L., Hebestreit K., et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Medicine 2012, 18(4):605-611.
198. Schmidt D.M., McCafferty D.G. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry 2007, 46(14):4408-4416.
199. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clinical Cancer Research 2006, 12(19):5777-5785.
200. Schulte J.H., Lim S., Schramm A., Friedrichs N., Koster J., Versteeg R., et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Research 2009, 69(5):2065-2071.
201. Schwartsmann G., Schunemann H., Gorini C.N., Filho A.F., Garbino C., Sabini G., et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Investigational New Drugs 2000, 18(1):83-91.
202. Segura-Pacheco B., Trejo-Becerril C., Perez-Cardenas E., Taja-Chayeb L., Mariscal I., Chavez A., et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clinical Cancer Research 2003, 9(5):1596-1603.
203. Shao Y., Gao Z., Marks P.A., Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proceedings of the National Academy of Science of the United States of America 2004, 101(52):18030-18035.
204. Sharif J., Muto M., Takebayashi S., Suetake I., Iwamatsu A., Endo T.A., et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 2007, 450(7171):908-912.
205. Sharma D., Blum J., Yang X., Beaulieu N., Macleod A.R., Davidson N.E. Release of methyl CpG binding proteins and histone deacetylase 1 from the estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Molecular Endocrinology 2005, 19(7):1740-1751.
206. Sharma S.K., Hazeldine S., Crowley M.L., Hanson A., Beattie R., Varghese S., et al. Polyamine-based small molecule epigenetic modulators. MedChemComm 2012, 3(1):14-21.
207. Sharma S.K., Wu Y., Steinbergs N., Crowley M.L., Hanson A.S., Casero R.A., et al. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators. Journal of Medicinal Chemistry 2010, 53(14):5197-5212.
208. Shen L., Pili R. Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. Oncoimmunology 2012, 1(6):948-950.
209. Shi Y. Histone lysine demethylases: Emerging roles in development, physiology and disease. Nature Reviews. Genetics 2007, 8(11):829-833.
210. Shi Y., Lan F., Matson C., Mulligan P., Whetstine J.R., Cole P.A., et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119(7):941-953.
211. Shi Y.J., Matson C., Lan F., Iwase S., Baba T., Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Molecular Cell 2005, 19(6):857-864.
212. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: From genes to behavior. Annual Review of Neuroscience 1999, 22:197-217.
213. Singal R., Ramachandran K., Gordian E., Quintero C., Zhao W., Reis I.M. Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clinical Genitourinary Cancer 2015, 13(1):22-31.
214. Singh M.M., Manton C.A., Bhat K.P., Tsai W.W., Aldape K., Barton M.C., et al. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. Neuro-Oncology 2011, 13(8):894-903.
215. Sorm F., Piskala A., Cihak A., Vesely J. 5-Azacytidine, a new, highly effective cancerostatic. Experientia 1964, 20(4):202-203.
216. Stathis A., Hotte S.J., Chen E.X., Hirte H.W., Oza A.M., Moretto P., et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clinical Cancer Research 2011, 17(6):1582-1590.
217. Steele N., Finn P., Brown R., Plumb J.A. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. British Journal of Cancer 2009, 100(5):758-763.
218. Stimson L., La Thangue N.B. Biomarkers for predicting clinical responses to HDAC inhibitors. Cancer Letters 2009, 280(2):177-183.
219. Stresemann C., Lyko F. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. International Journal of Cancer 2008, 123(1):8-13.
220. Tawbi H.A., Beumer J.H., Tarhini A.A., Moschos S., Buch S.C., Egorin M.J., et al. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: A phase I/II study and pharmacokinetic analysis. Annals of Oncology 2013, 24(4):1112-1119.
221. Taylor S.M., Jones P.A. Mechanism of action of eukaryotic DNA methyltransferase. Use of 5-azacytosine-containing DNA. Journal of Molecular Biology 1982, 162(3):679-692.
222. Tellez C.S., Grimes M.J., Picchi M.A., Liu Y., March T.H., Reed M.D., et al. SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome. International Journal of Cancer 2014, 135(9):2223-2231.
223. Tessarz P., Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nature Reviews. Molecular Cell Biology 2014, 15(11):703-708.
224. Thinnes C.C., England K.S., Kawamura A., Chowdhury R., Schofield C.J., Hopkinson R.J. Targeting histone lysine demethylases-Progress, challenges, and the future. Biochimica et Biophysica Acta 2014, 1839(12):1416-1432.
225. Van Triest B., Pinedo H.M., Giaccone G., Peters G.J. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Annals of Oncology 2000, 11(4):385-391.
226. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419(6907):624-629.
227. Vasilatos S.N., Katz T.A., Oesterreich S., Wan Y., Davidson N.E., Huang Y. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis 2013, 34(6):1196-1207.
228. Vendetti F.P., Topper M., Huang P., Dobromilskaya I., Easwaran H., Wrangle J., et al. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget 2015, 6(1):56-70.
229. Venturelli S., Armeanu S., Pathil A., Hsieh C.J., Weiss T.S., Vonthein R., et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007, 109(10):2132-2141.
230. Verdin E., Dequiedt F., Kasler H.G. Class II histone deacetylases: Versatile regulators. Trends in Genetics 2003, 19(5):286-293.
231. Volkel P., Dupret B., Le Bourhis X., Angrand P.O. Diverse involvement of EZH2 in cancer epigenetics. American Journal of Translational Research 2015, 7(2):175-193.
232. Vujcic S., Liang P., Diegelman P., Kramer D.L., Porter C.W. Genomic identification and biochemical characterization of the mammalian polyamine oxidase involved in polyamine back-conversion. The Biochemical Journal 2003, 370(Pt. 1):19-28.
233. Walport L.J., Hopkinson R.J., Schofield C.J. Mechanisms of human histone and nucleic acid demethylases. Current Opinion in Chemical Biology 2012, 16(5-6):525-534.
234. Wang L., Amoozgar Z., Huang J., Saleh M.H., Xing D., Orsulic S., et al. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model. Cancer Immunology Research 2015, 3(9):1030-1041.
235. Wang Y., Devereux W., Woster P.M., Stewart T.M., Hacker A., Casero R.A. Cloning and characterization of a human polyamine oxidase that is inducible by polyamine analogue exposure. Cancer Research 2001, 61(14):5370-5373.
236. Wang Y., Hacker A., Murray-Stewart T., Frydman B., Valasinas A., Fraser A.V., et al. Properties of recombinant human N1-acetylpolyamine oxidase (hPAO): Potential role in determining drug sensitivity. Cancer Chemotherapy and Pharmacology 2005, 56(1):83-90.
237. Wang J., Hevi S., Kurash J.K., Lei H., Gay F., Bajko J., et al. The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nature Genetics 2009, 41(1):125-129.
238. Wang J., Scully K., Zhu X., Cai L., Zhang J., Prefontaine G.G., et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature 2007, 446(7138):882-887.
239. Weiss J.W., Pitot H.C. Effects of 5-azacytidine on nucleolar RNA and the preribosomal particles in Novikoff hepatoma cells. Biochemistry 1975, 14(2):316-326.
240. Wilson B.G., Wang X., Shen X., McKenna E.S., Lemieux M.E., Cho Y.J., et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 2010, 18(4):316-328.
241. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Letters 2009, 277(1):8-21.
242. Witt O., Lindemann R. HDAC inhibitors: Magic bullets, dirty drugs or just another targeted therapy. Cancer Letters 2009, 280(2):123-124.
243. Wong M.M., Guo C., Zhang J. Nuclear receptor corepressor complexes in cancer: Mechanism, function and regulation. American Journal of Clinical and Experimental Urology 2014, 2(3):169-187.
244. Wrangle J., Wang W., Koch A., Easwaran H., Mohammad H.P., Vendetti F., et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 2013, 4(11):2067-2079.
245. Xia C., Leon-Ferre R., Laux D., Deutsch J., Smith B.J., Frees M., et al. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemotherapy and Pharmacology 2014, 74(4):691-697.
246. Yang M., Culhane J.C., Szewczuk L.M., Gocke C.B., Brautigam C.A., Tomchick D.R., et al. Structural basis of histone demethylation by LSD1 revealed by suicide inactivation. Nature Structural & Molecular Biology 2007, 14(6):535-539.
247. Yang M., Culhane J.C., Szewczuk L.M., Jalili P., Ball H.L., Machius M., et al. Structural basis for the inhibition of the LSD1 histone demethylase by the antidepressant trans-2-phenylcyclopropylamine. Biochemistry 2007, 46(27):8058-8065.
248. Yang M., Gocke C.B., Luo X., Borek D., Tomchick D.R., Machius M., et al. Structural basis for CoREST-dependent demethylation of nucleosomes by the human LSD1 histone demethylase. Molecular Cell 2006, 23(3):377-387.
249. Yang D., Torres C.M., Bardhan K., Zimmerman M., McGaha T.L., Liu K. Decitabine and vorinostat cooperate to sensitize colon carcinoma cells to Fas ligand-induced apoptosis in vitro and tumor suppression in vivo. Journal of Immunology 2012, 188(9):4441-4449.
250. Yang W.M., Tsai S.C., Wen Y.D., Fejer G., Seto E. Functional domains of histone deacetylase-3. The Journal of Biological Chemistry 2002, 277(11):9447-9454.
251. Yao Y., Chen P., Diao J., Cheng G., Deng L., Anglin J.L., et al. Selective inhibitors of histone methyltransferase DOT1L: Design, synthesis, and crystallographic studies. Journal of the American Chemical Society 2011, 133(42):16746-16749.
252. Yardley D.A., Ismail-Khan R.R., Melichar B., Lichinitser M., Munster P.N., Klein P.M., et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. Journal of Clinical Oncology 2013, 31(17):2128-2135.
253. Yoo C.B., Chuang J.C., Byun H.M., Egger G., Yang A.S., Dubeau L., et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prevention Research (Philadelphia) 2008, 1(4):233-240.
254. You A., Tong J.K., Grozinger C.M., Schreiber S.L. CoREST is an integral component of the CoREST-human histone deacetylase complex. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(4):1454-1458.
255. Zhang J., Kalkum M., Chait B.T., Roeder R.G. The N-CoR-HDAC3 nuclear receptor corepressor complex inhibits the JNK pathway through the integral subunit GPS2. Molecular Cell 2002, 9(3):611-623.
256. Zhang Y., Ng H.H., Erdjument-Bromage H., Tempst P., Bird A., Reinberg D. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes & Development 1999, 13(15):1924-1935.
257. Zhou L., Cheng X., Connolly B.A., Dickman M.J., Hurd P.J., Hornby D.P. Zebularine: A novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. Journal of Molecular Biology 2002, 321(4):591-599.
258. Zhu Q., Huang Y., Marton L.J., Woster P.M., Davidson N.E., Casero R.A. Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids 2012, 42(2-3):887-898.
259. Zhu W.G., Lakshmanan R.R., Beal M.D., Otterson G.A. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Research 2001, 61(4):1327-1333.